October 9, 2026
Dive Brief: Cartesian Therapeutics on Tuesday said an experimental cell therapy it’s developing succeeded in a mid-stage clinical trial of
Two of last year’s largest biotechnology company acquisitions centered on a new type of treatment for schizophrenia. By the end
Today, a brief rundown of news from Beacon Therapeutics and Regeneron Pharmaceuticals, as well as updates from Vertex Pharmaceuticals, Johnson
Dive Brief: CureVac, a specialist in messenger RNA-based therapies, disclosed Wednesday plans to lay off 30% of its workforce as
The U.S. government has awarded $176 million to vaccine maker Moderna for development of an mRNA-based influenza shot. The funding
The Food and Drug Administration on Tuesday approved a new Alzheimer’s disease drug from Eli Lilly, several weeks after a
Dive Brief: Eisai and Bristol Myers Squibb will cancel a collaboration on a dual-acting drug being developed to treat lung
Dive Brief: Eli Lilly is expanding further into radiopharmaceuticals, inking a deal with Radionetics Oncology that gives it an option
Viral contamination is a threat to biopharmaceutical product development.1 Contaminants can be present in the cells and source materials or
Dive Brief: 2seventy Bio is shrinking further, announcing Thursday the sale of a hemophilia A research program, along with associated
Dive Brief: The U.S. Supreme Court overturned the Chevron doctrine on Friday in a decision that could dramatically limit federal
Today, a brief rundown of news from PTC Therapeutics, Esperion Therapeutics and Coherus Biosciences, as well as updates from Sanofi,
Dive Brief: The Food and Drug Administration has rejected a gene therapy developed by Rocket Pharmaceuticals for a rare type
Dive Brief: Advisers to the Centers for Disease Control and Prevention on Thursday unanimously recommended Merck & Co.’s recently approved
Immune drug developer Alumis has raised $210 million in one of the biotechnology sector’s largest initial public offerings this year.
Dive Brief: Shares of Moderna, Pfizer and GSK fell as advisers to the Centers for Disease Control and Prevention discussed
Ozempic and GLP-1 drugs like it became household names due to their potent weight loss benefits, and are now proving
Dive Brief: Novo Nordisk will end a Phase 3 clinical trial of a hypertension drug it bought for up to
Dive Brief: Wave Life Sciences on Tuesday said it will meet with regulators to discuss what kind of evidence would
Dive Brief: Novo Nordisk will spend $4.1 billion to build a new U.S. factory in North Carolina, the latest multibillion-dollar
Exsilio Therapeutics, a biotechnology startup led by a former Moderna executive, emerged from stealth Tuesday with an approach it claims
Today, a brief rundown of news from Altimmune, Jiangsu Hengrui, Eli Lilly and others that you might have missed from over
Diseases aren’t just disorders in physiological systems, and it’s not possible to cure them simply by discovering molecules with therapeutic
Dive Brief: Amazon has expanded its generic drug savings program to Prime members on Medicare, throwing open the program’s doors
Dive Brief: Twice-yearly shots of a Gilead Sciences HIV drug were so effective at preventing infections in a large late-stage
Dive Brief: PTC Therapeutics said Thursday it can resume a Phase 2 trial of its Huntington’s disease drug in the
Today, a brief rundown of news from Jazz Pharma, Vanda Pharmaceuticals, ITM, Ashibio and Novartis that you might have missed
Peter Marks is again at the center of a controversial Food and Drug Administration decision on a gene therapy for
An experimental weight loss shot developed by Denmark-based Zealand Pharma helped people with obesity lose as much as 9% of
The Food and Drug Administration has substantially loosened limits on the first gene therapy for Duchenne muscular dystrophy in a
Today, a brief rundown of news from Belharra Therapeutics, AstraZeneca, Regenxbio and Tasyha Gene Therapies. Sanofi will work with biotechnology
Dive Brief: Intra-Cellular Therapies plans to seek clearance to sell its medicine Caplyta for patients with depression after a second-late
Dive Brief: The Food and Drug Administration on Monday approved a new vaccine from Merck & Co. that protects against
The failure of a Pfizer medicine for Duchenne muscular dystrophy adds new uncertainty around the effectiveness of gene therapy for
Today, a brief rundown of news from Takeda and the Food and Drug Administration, as well as updates from Insmed,
Dive Brief: Telix, an Australia-based developer of radiopharmaceutical drugs for cancer, has canceled plans to raise roughly $200 million via
AbbVie is securing its place in an emerging gastrointestinal disease drug field, paying China-based FutureGen Biopharmaceutical $150 million in immediate
Dive Brief: Moderna said its next-generation COVID-19 vaccine succeeded in a Phase 3 study, offering increased effectiveness for adults. The
The Supreme Court on Thursday unanimously ruled an anti-abortion group contesting the Food and Drug Administration’s approval of the abortion
Precision immunology has emerged as one of the hottest fields in drugmaking over the past several years, spurred by new
Pfizer’s experimental gene therapy for Duchenne muscular dystrophy didn’t improve the motor function of young boys enrolled in a late-stage
Foresite Capital, an investment firm that backs life sciences and healthcare companies, has raised a $900 million fund. The fund,
Approval of Eli Lilly’s experimental Alzheimer’s disease drug donanemab would help drive sales of Eisai and Biogen’s rival medicine Leqembi,
Dive Brief: Moderna on Monday said a combination flu and COVID-19 shot it’s developing met the goal of a late-stage
An experimental and closely watched medicine for Alzheimer’s disease is one step closer to approval, after receiving support from a
As healthcare moves toward the shared goal of improving patient care more economically, stakeholders across the healthcare ecosystem are increasingly
Dive Brief: Seres Therapeutics plans to sell all the rights to its microbiome pill to Nestlé Health Science as it
A group of advisers to the Food and Drug Administration on Wednesday unanimously recommended that COVID-19 vaccines be updated to
After a turbulent few years, 2024 has given the biotechnology industry some signs of a return to normalcy. For one,
Today, several brief updates from BioPharma Dive Reporter Gwendolyn Wu, who spent this week attending BIO’s annual meeting in San
Long dismissed by top scientists and drug regulators, the use of psychedelics to treat mental health conditions has finally gained
Dive Brief: Expert advisers to the Food and Drug Administration will need to weigh whether Eli Lilly’s experimental Alzheimer’s disease
Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback. British drugmaker
Dive Brief: Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior
Today, a brief rundown of news from Eli Lilly, Cytokinetics and AbbVie, as well as updates from Gilead and the
Dive Brief: Illumina’s board of directors has approved a spinoff of Grail, targeting June 24 as the date the cancer
Medical experts who advise the Food and Drug Administration are not convinced MDMA is ready for general use to help
Dive Brief: An experimental GLP-1 pill helped people with obesity lose significantly more weight than a placebo over three months,
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what
Liquid biopsy has emerged as a revolutionary tool for clinical trials, offering cellular and cell-free methods that provide valuable insights
AstraZeneca’s immunotherapy Imfinzi helped people in the early stages of a type of lung cancer live 23 months longer than
Two years ago, a drug called Enhertu changed the way doctors thought about treating an aggressive form of breast cancer,
The Food and Drug Administration on Friday approved a third vaccine for respiratory syncytial virus, clearing a shot from biotechnology
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what
Food and Drug Administration scientists have reservations about a potential new treatment for post-traumatic stress disorder that’s currently up for
People with chronic myeloid leukemia, a simmering cancer of the bone marrow, are often treated with one of several targeted
Dive Brief: Immunovant told investors Wednesday that it’s shifting resources to focus on a less advanced experimental autoimmune disease treatment
Dive Brief: Merck & Co. on Wednesday said it has agreed to buy privately held eye drug developer EyeBio for
Dive Brief: Gameto, a biotechnology company developing new treatments for fertility, has raised $33 million in venture capital funding to
Dive Brief: Agios Pharmaceuticals has agreed to sell to Royalty Pharma rights to royalties on a brain cancer drug it
New Jersey-based drugmaker Insmed gained more than $3 billion in market value Tuesday after reporting clinical trial results for an
Artificial intelligence (AI) has sparked a revolution in the pharmaceutical industry, reshaping the way we approach complex biological challenges. “From
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what
Dive Brief: Shares in Cytokinetics sank by about one-fifth Thursday on news of a funding deal the biotechnology company struck
Dive Brief: German drugmaker Merck KGaA agreed to buy Mirus Bio for $600 million to build expertise in a critical
Orna Therapeutics, a young biotechnology company focused on a flashy area of genetic research, is expanding through the acquisition of
Eli Lilly plans to spend another $5.3 billion building production capacity for its popular obesity and diabetes drugs, responding to
A top Food and Drug Administration official on Friday again advocated for the speedy approval of gene therapies for rare
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what
An older form of hormone therapy taken to ease the symptoms of menopause could increase the risk of ovarian cancer,
Dive Brief: Biogen is scooping up a closely held immunology startup to bring more diversity to a pipeline best known
Pfizer, already in the midst of an aggressive effort to trim spending, on Wednesday disclosed new plans to cut at
Eli Lilly is partnering with biotechnology company Aktis Oncology to develop radiopharmaceuticals for cancer, agreeing to a deal that will
Dive Brief: AstraZeneca’s plan to reach $80 billion in sales by 2030 relies heavily on a slate of roughly one
British biotechnology startup Pheon Therapeutics has raised another $120 million in venture funding, riding a wave of investor interest in
Forbion, a well-known backer of life sciences startups, is leading an investment round for a newly launched biotechnology company focused
Dr. Zocca brings more than 20 years of experience in the biotechnology field and has founded and co-founded several biotech
Biogen and Ionis Pharmaceuticals are stopping development of an experimental drug for ALS following new clinical trial results that didn’t
Dive Brief: An experimental Roche drug helped people with obesity lose an average of nearly 19% of their body weight
A once-weekly form of insulin being developed by Eli Lilly proved just as effective at controlling blood sugar in adults
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what
Dive Brief: The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to
Four life science investors are pouring $400 million into a new biotechnology startup that’s licensed a portfolio of weight loss
New data from two late-stage studies of an experimental Bayer drug show it reduced the frequency and severity of common
San Francisco-based Bolt Biotherapeutics on Tuesday said it is ending development of its lead cancer drug, laying off half its
One of the developers behind the Alzheimer’s disease drug Leqembi has set new revenue expectations that some analysts see as
FogPharma and Artbio, two buzzy biotechnology companies, are betting they can combine their respective technologies to design a new type
German pharmaceutical company Bayer eliminated 1,500 roles during the first three months of the year as part of a company
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief:
Takeda Pharmaceutical is betting potentially billions of dollars on drugs designed to slow Alzheimer’s disease by harnessing the immune system.
Medicines called JAK inhibitors are well known in the pharmaceutical industry. Several are approved to treat inflammatory disease conditions or
Novo Nordisk is again turning to a Flagship Pioneering startup to find new weight loss drugs, announcing on Thursday a
Dive Brief: Sanofi will pay vaccine maker Novavax $500 million and take a small equity stake in the Maryland-based company
Dive Brief: Biotechnology startup Maze Therapeutics has licensed a Pompe disease drug to Shionogi, five months after a challenge from
Moderna on Friday said the Food and Drug Administration has postponed an approval decision on its experimental vaccine for respiratory
BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what
Dive Brief: Royalty Pharma will pay biotechnology startup ImmuNext $525 million for the right to earn royalties and milestone payments
Dive Brief: Takeda plans to simplify how its workforce is organized, cut spending and slim down its drug pipeline in
Dive Brief: AstraZeneca will no longer manufacture or supply its COVID-19 vaccine Vaxzevria, announcing Tuesday it is voluntarily withdrawing the shot
Patents reward drugmakers for their inventions and, effectively, the large sums of money they invest in research and development. The
Dive Brief: Verve Therapeutics has treated the first participant in a recently begun clinical trial of the company’s backup gene
A young boy enrolled in a clinical trial testing an experimental Pfizer gene therapy for Duchenne muscular dystrophy has died,
Dive Brief: Flagship Pioneering on Tuesday launched Prologue Medicines, a new biotechnology startup aiming to make drugs by closely studying
Gossamer Bio has sold rights to an experimental drug that could rival a new medicine from Merck & Co., in
When it comes to data-driven science, your results are only as good as your data and your software. Whether free
Cancer research is always evolving, as scientists search for ways to combat the tricks tumors use to evade drug therapies.
Dive Brief: The gene editing company Metagenomi, which went public earlier this year, said a development partnership struck with Moderna
Dive Brief: An experimental drug from CG Oncology has driven bladder cancers into remission in about three-quarters of people who
Mariana Oncology arrived at the J.P. Morgan Healthcare Conference this past January with momentum. The radiopharmaceutical drug developer had secured
Dive Brief: Amgen shares soared by double digits Friday following its announcement an obesity drug it’s developing has shown enough
Dive Brief: Novartis is expanding its pipeline of radiopharmaceutical drugs, announcing Thursday it has agreed to pay $1 billion to
Dive Brief: Sales of Novo Nordisk’s obesity drug Wegovy slowed over the first three months of 2024, compared to the
Pfizer’s rare disease drug Vyndaqel may be its least well known blockbuster medicine. The pharmaceutical company’s COVID-19 vaccine became a
Dive Brief: GSK on Wednesday raised its financial forecasts for the year following strong quarterly sales of its vaccines and
Federal officials said a new rule expanding regulatory oversight of laboratory-developed tests will protect patients from inaccurate results while maintaining
Eli Lilly expects that, by the second half of this year, it will be able to manufacture at least 50%
Dive Brief: Prime Medicine will soon begin the first clinical trial of a new drugmaking technique known as prime editing,
Dive Brief: The Food and Drug Administration on Monday released a final rule strengthening its authority over laboratory developed tests,
Sponsors and clinical researchers have been voicing a desire to adopt patient-centric approaches to drug development for more than a decade,
Dive Brief: Biogen has seen “encouraging early trends” in the launch of its postpartum depression pill Zurzuvae, revealing in first
Dive Brief: Regeneron Pharmaceuticals is upping its investment in genetic medicine, announcing Thursday a $100 million deal with CRISPR drug
Bristol Myers Squibb will cut 6% of its workforce in a restructuring meant to save $1.5 billion in costs by
Dive Brief: The Food and Drug Administration on Friday approved a new gene therapy for hemophilia, clearing Pfizer’s Beqvez for
Dive Brief: U.S. Humira sales fell 40% year over year during the first three months of 2024, to about $1.8
Dive Brief: BioMarin on Wednesday said it’s wrapped up a pipeline review and will stop investing in four experimental therapies
AstraZeneca’s revenue and profits grew at a rapid clip over the first three months of the year, beating Wall Street
Moderna is betting big on bespoke artificial intelligence assistants. The biotechnology company on Wednesday said it has expanded a partnership
Investors who had hoped Biogen would do another flashy deal this year may not want to hold their breath, as
Sales of Novartis drugs for heart failure, psoriasis and multiple sclerosis were stronger over the first three months of the
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which
Dive Brief: Eli Lilly on Monday said it will acquire a drug plant from Nexus Pharmaceuticals to expand its manufacturing
Dive Brief: French pharmaceutical company Ipsen will work with privately held biotechnology company Skyhawk Therapeutics to make small molecule drugs
For patients diagnosed with rare diseases or chronic illnesses, treatment delays can seriously impact health outcomes. A meta-analysis of cancer
Dive Brief: Alvotech and Teva on Tuesday won Food and Drug Administration approval for Selarsdi, the second biosimilar poised to
Dive Brief: Metsera, a richly funded biotechnology startup, launched Thursday with a portfolio of weight loss drugs the company claims
Cerevel Therapeutics, a biotechnology company in the midst of being acquired by AbbVie, on Thursday said a Parkinson’s disease treatment
The Food and Drug Administration has made a medicine from Roche the first specifically available for early treatment of lung
Dive Brief: Alvotech and U.S. commercial partner Teva have signed a “long-term agreement” with an unspecified company to boost access
Vertex Pharmaceuticals is vying for approval of an experimental and closely watched painkiller that could become an alternative to addictive
Dive Brief: 23andMe CEO Anne Wojcicki plans to take the DNA testing company private, according to a Wednesday filing with
An experimental drug designed to improve brain function in people with nerve-degrading disorders has failed a mid-stage study that tested
Fresh clinical trial results for Eli Lilly’s drug Zepbound point to a new use for the weight loss medicine in
An antipsychotic drug from Intra-Cellular Therapies appears to also work as an add-on therapy for depression, according to clinical trial
Dive Brief: Sales of Johnson & Johnson’s multiple myeloma medicine Tecvayli more than doubled in the first quarter versus the
Shares of Neumora Therapeutics fell Monday after the company disclosed a small clinical trial testing one of its experimental medicines
Dive Brief: Roche’s new dual-acting blood cancer drug Columvi combined with chemotherapy helped people with a type of lymphoma live
When Katherine Wisner began studying postpartum mental health in the 1980s, the field barely existed. Relatively little research was focused
Dive Brief: Biotechnology company Rallybio is partnering with Johnson & Johnson, announcing a collaboration Wednesday to develop new treatments for
Dive Brief: Genentech, the research subsidiary of Swiss pharmaceutical giant Roche, has decided to cut short a partnership focused on
Initial public offerings by biotechnology companies reached pre-pandemic levels during the first quarter, with nine drugmakers collectively raising more than
Dive Brief: Novo Nordisk and Eli Lilly drugs to treat diabetes and obesity have no “causal association” with suicidal thoughts
The U.S. Department of Justice on Wednesday accused Regeneron of defrauding Medicare by knowingly inflating the average sales price for
Dive Brief: Biotechnology company Century Therapeutics is expanding its autoimmune disease research with a pair of deals that will hand
Dive Brief: Vertex Pharmaceuticals on Wednesday said it would buy biotechnology company Alpine Immune Sciences and its experimental kidney disease
Dive Brief: Novartis will pause enrollment in certain clinical trials of its breast cancer drug Kisqali in order to meet
Dive Brief: Pfizer on Tuesday said it plans to ask regulators to broaden the approval of its vaccine for respiratory
Hoping to repeat a recent success story, the biotechnology startup creator PureTech Health has launched a new company aimed at
Private funding for biotechnology startups rose during the first three months of the year, suggesting some of the sector’s momentum
Dive Brief: Novo Nordisk’s weight loss drug Wegovy helped people with obesity, diabetes and heart failure have fewer cardiovascular symptoms
Dive Brief: Genmab said Wednesday it’s agreed to pay $1.8 billion for ProfoundBio, gaining access to the biotechnology startup’s technology
Amylyx Pharmaceuticals is pulling from market one of the few approved treatments for ALS. Rarely do drugmakers voluntarily withdraw products.
Dive Brief: Swiss drugmaker Basilea Pharmaceutica on Wednesday won Food and Drug Administration approval for its drug Zevtera in a
Johnson & Johnson has agreed to acquire Shockwave Medical for approximately $13.1 billion, the companies announced Friday morning. The deal
Dive Brief: The Food and Drug Administration has cleared Bristol Myers Squibb and 2seventy Bio’s multiple myeloma cell therapy for
Dive Brief: Boehringer Ingelheim is laying off staff in response to sluggish adoption of its Humira biosimilar Cyltezo, a company
Contineum Therapeutics has raised $110 million in an initial public offering, the biotechnology industry’s 10th of the year, to advance
Dive Brief: Merck & Co. has begun a large clinical trial testing an experimental cancer drug it’s developing for tumors
Dive Brief: A third biotechnology company from the startup creator Paragon Therapeutics is heading to the public markets. Paragon’s Oruka
Dive Brief: Acorda Therapeutics has filed for bankruptcy and, on Monday, announced it has reached an agreement to sell essentially
Dive Brief: An experimental drug being developed by a subsidiary of Roivant Sciences succeeded in a Phase 2 trial testing
The year started well for the biotechnology industry. Steady dealmaking coupled with a rebound in initial public offerings helped lift
Dive Brief: Vertex Pharmaceuticals on Monday said it will advance an experimental kidney disease drug into Phase 3 testing and
The Food and Drug Administration on Tuesday approved a new Merck & Co. drug to treat pulmonary arterial hypertension. Called
A large clinical trial has found that a drug commonly used by patients with ALS is not effective at treating
Two years after Art Krieg sold his last biotechnology company to Regeneron Pharmaceuticals, the scientific entrepreneur and industry veteran is
When the Food and Drug Administration expanded approval of Novo Nordisk’s weight loss medicine Wegovy to also protect heart health,
Dive Brief: Bristol Myers Squibb’s cancer pill Krazati helped people with a certain kind of non-small cell lung cancer live
Dive Brief: Gilead Sciences will pay $30 million and invest another $13.5 million in Xilio Therapeutics to access an experimental
Dive Brief: The Food and Drug Administration has approved Akebia Therapeutics’ blood-boosting pill Vafseo for people with anemia from chronic kidney
Dive Brief: Boundless Bio, a cancer drug developer backed by Bayer and Arch Venture Partners, has raised $100 million in
Dive Brief: Blackstone Life Sciences will invest as much as $750 million on influenza vaccine research and development by Moderna,
The Supreme Court on Tuesday heard legal arguments in a high-profile case involving the Food and Drug Administration’s expanded approval
Dive Brief: A dual-acting weight loss pill from Viking Therapeutics helped people with obesity lose up to 5% of their
An experimental drug from Axsome Therapeutics was successful in a late-stage clinical trial evaluating it as a treatment for narcolepsy
Dive Brief: Abbvie is expanding its pipeline of inflammatory disease drugs, announcing Monday a small deal to acquire biotechnology company
Capstan Therapeutics, a biotechnology startup developing medicines that reprogram cells inside the body, has raised another $175 million to bring
The executives behind autoimmune drug developer Prometheus Biosciences are back, armed with more than $400 million to launch their latest
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief:
Dive Brief: Thermo Fisher Scientific said Wednesday that it has partnered with Bayer to develop companion diagnostic assays for the
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Medicare will